Genmab A/S (NASDAQ:GMAB) Sets New 12-Month Low - Time to Sell?

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $19.27 and last traded at $19.08, with a volume of 38725 shares. The stock had previously closed at $20.80.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research reports. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating for the company. BMO Capital Markets reissued an "outperform" rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Price Performance

The company has a market capitalization of $13.08 billion, a P/E ratio of 19.23, a PEG ratio of 0.57 and a beta of 0.97. The business's 50-day moving average price is $21.06 and its two-hundred day moving average price is $23.79.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter last year, the company earned $0.47 EPS. Research analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Advisers LP lifted its stake in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares in the last quarter. FMR LLC lifted its position in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Genmab A/S by 6.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company's stock worth $5,662,000 after purchasing an additional 14,165 shares during the last quarter. Natixis Advisors LLC grew its position in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after purchasing an additional 47,437 shares in the last quarter. Finally, ABC Arbitrage SA acquired a new stake in Genmab A/S in the 4th quarter valued at $3,692,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.